1. Introduction: cancer as a developmental disorder {#sec1}
===================================================

A defining feature of multicellular life is pattern homeostasis: the establishment and maintenance of a complex bodyplan during embryogenesis, and its upkeep during remodeling, wound healing, and aging. Some animals have developed this property to a remarkable degree, such as salamanders that fully regenerate amputated limbs, eyes, jaws, and spinal cords \[[@r1]-[@r3]\]. The single thread that connects all of these processes is the need to subjugate single cell activities to the anatomical needs of the host organism. Cell proliferation, differentiation, migration, apoptosis, and other functions are normally harnessed to large-scale morphogenesis by a complex system of instructive cues that functionally determines cell behavior. This morphodynamic field \[[@r4]\] is the sum total of signals that impinge upon cells *in vivo*, carrying information from distant regions that is necessary for cells to implement coordinated patterning at a large scale (Fig. **[1](#F1){ref-type="fig"}**). It has long been recognized that such a process necessarily runs a risk of cells becoming unable to interact properly with the somatic bodyplan \[[@r5]-[@r7]\]. This would result in cells reverting to a unicellular mode in which they survive and multiply as any life form tries to do, at the expense of the environment within which it lives \[[@r8], [@r9]\]. Thus, one view of cancer is as a developmental disorder \[[@r7], [@r10]-[@r13]\]: a network disease of the complex signaling pathways that normally keep cells away from tumorigenesis and toward correct anatomical structure. Supporting this view is an evidence that regenerative and embryonic environments, which feature very strong instructive patterning influences applied to cells, are well-known to be able to normalize tumor cells (Fig. **[2](#F2){ref-type="fig"}**, \[[@r14]-[@r16]\] and \[[@r17]\]).

Here, we focus on the role of one signaling modality that underlies this multiscale pattern regulation: non-neural bioelectricity \[[@r18]-[@r21]\]. It is perhaps not widely appreciated that the use of electrical signaling by the brain is not an original invention: nervous systems evolved by exploiting ionic signaling that was ancient, and used by many kinds of cells to coordinate physiological signaling, aneural behavior patterns, and morphogenesis \[[@r22], [@r23]\]. Ion channels and electrical synapses (gap junctions, which function alongside the more familiar chemical synapses, especially outside the CNS) (Fig. **[3](#F3){ref-type="fig"}**) are widely-expressed throughout metazoan bodies, and the resulting electrical dynamics are an important regulatory modality for cell number, cell shape, differentiation, and morphogenesis \[[@r24]\]. Differences in cells' resting potentials (V~mem~) across anatomical distances (Fig. **[4](#F4){ref-type="fig"}**) result in instructive physiological prepatterns that determine gene expression domains and subsequent morphogenesis, for example in craniofacial patterning \[[@r25], [@r26]\] and axial polarity during regeneration \[[@r27], [@r28]\]. Crucially (Fig. **[5](#F5){ref-type="fig"}**), bioelectric signals play a role in long-range coordination of growth and form, regulating the size of brains \[[@r29]\], appendages \[[@r30]\], and even kickstarting the appearance of whole organs \[[@r31], [@r32]\]. Thus, many of the endpoints that go awry in cancer, including overproliferation, dedifferentiation, vascular patterns, chromatin changes, gene expression, and migratory behavior are all known to be downstream of the activity of bioelectric circuits during normal pattern regulation \[[@r18], [@r21]\].

Each cell *in vivo* exists within a complex field of information imposed on it by the host organism. This set of signals, impinging on cells from 3 dimensions and varying in time, is mediated by a number of physical properties, including gradients of diffusible chemical messengers, extracellular matrix properties (ECM), tensile/pressure forces, and bioelectric states. The sum total of these instructive cues are responsible for establishment of normal somatic pattern during embryogenesis, and for harnessing cell activity toward the anatomical needs of the host organism throughout its life. It guides cell behaviors during regeneration, remodeling, and on-going pattern homeostasis; the interactions of cells with this guidance system reveals a key common feature among development, regeneration, and cancer, all of which are fundamentally problems of spatio-temporal organization and the imposition of global order on local cell activity. It may be that cancer can be efficiently understood as a disorder of cells' communication with this field (either because the signals become absent from a region of the environment, or because cells become inattentive to its informational influence); in turn, re-establishing correct morphogenetic cues and forcing cell communication with this set of cues may be a path forward for tumor normalization/reprogramming.

Changes in the biophysical parameter V~mem~ can be transduced into downstream transcriptional responses by the voltage-regulated movement of neurotransmitter molecules across cell membranes and between cells through gap junctions. These electrical synapses, like ion channels, are ancient and widely present outside the nervous system \[[@r33], [@r34]\]. Molecules such as serotonin have pre-neural roles, such as in gastrulation, determination of left-right patterning, craniofacial development, and cardiac morphogenesis \[[@r35]-[@r42]\]. Together, ion channels, gap junctions, and neurotransmitter signaling machinery form somatic bioelectric circuits that coordinate cell behaviors toward prescribed and limited tissue-level outcomes. One of the key aspects of this control system is that it is fundamentally epigenetic, operating at the level of ion flows and channel gating and invisible in fixed samples or from profiling of transcriptional or translational states. In some cases, this physiological layer dominates genomic defaults; appropriate bioelectric manipulation can rescue normal brain patterning despite defects in important neurogenesis genes such as *Notch* \[[@r29]\], induce regeneration of spinal cord in non-regenerative animals \[[@r43], [@r44]\], convert normally non-permissive tissue such as gut into complete eyes \[[@r32]\], and alter the shape \[[@r27]\] and number \[[@r45], [@r46]\] of heads in regenerating animals.

These data on multi-cellular reprogramming suggest that targeting physiology, not only genetics, may be an effective and dominant strategy for diagnostics and control of cancer. The ability to trigger coherent change in thecell fields into a whole organ \[[@r32]\] or starting the growth of a complex appendage with a simple gradient change \[[@r43], [@r44]\] suggests that it may be possible to trigger modular patterning: exert organ-level control over a body region without having to micromanage each cell. Long-term, this may be part of a strategy to mimic the ability of regeneration or development to provide patterning cues that dominate individual cell fate and normalize tumors. Thus, we proposed the hypothesis that exploiting the bioelectrical system by which cells coordinate their constraints on growth could lead to advances in cancer biology.

2. Bioelectrics and cancer {#sec2}
==========================

Interestingly, while the importance of steady-state V~mem~ is only recently becoming understood, true neural-like excitability in cancer cells was discovered over 20 years ago \[[@r47], [@r48]\]. Aside from spiking, steady-state resting potentials are an important regulatory factor (Fig. **[6](#F6){ref-type="fig"}**): tumor cells tend to be more depolarized than their normal counterparts (complicated by the fact that Vmem tends to fluctuate somewhat during the mitotic phases, reviewed in \[[@r49]\]), and experimental modulation of resting potential can functionally normalize cells and prevent or reverse tumorigenesis \[[@r50]-[@r52]\]. Recent work has extended this observation into testing roles of individual ion channels as *bona fide* oncogenes (Table **[1](#T1){ref-type="table"}**), ion channel expression profiles as markers \[[@r53], [@r54]\], and drug approaches targeting specific channels for cancer therapeutics \[[@r55]\]. Role of gap junctions in cancer has been covered extensively \[[@r56], [@r57]\], and these too are currently an exciting target for cancer therapies \[[@r58], [@r59]\].

Subsequent experiments suggested roles of resting potential per se (generated by one of any number of electrogenic proteins) in activating or suppressing cancer-relevant processes *in vivo*. Most of these data remain to be validated in mammalian models, being first derived in the frog *Xenopus laevis* \[[@r17]\]. Artificial depolarization of a selected cell population of cells was sufficient to induce a melanoma-like phenotype in normal animals' pigment cell population \[[@r60], [@r61]\]. This metastatic conversion (Fig. **[7](#F7){ref-type="fig"}**) takes place in a wild-type background, not exposed to any mutagen or carcinogen; it features stochastic outcomes within a cohort of animals exposed to the same manipulation \[[@r62]\], and may be a model for the variability of cancer incidence in clinical settings.

Conversely, tumorigenesis induced by expression of human oncogenes in frog larvae can be over-ridden by appropriate modulation of resting potential \[[@r63]\]. This also works at considerable distance *via* a gap junction-dependent mechanism \[[@r64], [@r65]\], and tumors can be prevented or reverted to normal by pharmacological, genetic, or even light-based stimuli (Fig. **[8](#F8){ref-type="fig"}**) that induce hyperpolarization \[[@r65], [@r66]\]. This was another example of the over-riding of genetic state by physiological parameters, as the mutant oncogene was strongly present in the regions in which tumorigenesis was prevented. In normal cases, the appearance of tumor structures can be observed very early, by fluorescent signals from a voltage reporting dye \[[@r60]\].

A few overall lessons emerged from this most recent body of work. First, that it is imperative to focus on the physiological state (V~mem~ and cellular connectivity), not individual channel genes, since channels open and close post-translationally, while V~mem~ is the sum of numerous channels' activity. Thus, the same effect can be obtained *via* the action of any number of channels that contribute to overall resting potential, and V~mem~ can change in the absence of detectable changes of channel mRNA or protein levels. Thus, tracking individual channels or using profiling of fixed (non-living) tissue can give confusing results due to the lack of one-to-one correspondence between genetic and physiological states. Second, the effects are often non-local: metastatic or tumorigenic outcomes can be a function of bioelectric states at considerable distances -- the signaling is definitely not cell-autonomous, although the maximum distance (size of the "microenvironment") that might be involved in mammals is unknown. Finally, that the physiological signaling of the environment is a key determinant of outcome which cannot be predicted from molecular profiling alone.

We suggest that the multitude of ion channel drugs, many of which are already approved for human use (as antiepileptics, antiarrhythmic agents, *etc*.) and some of which are kept on pharmaceutical company shelves, form a powerful toolkit. These compounds are potential electroceuticals; while such approaches have so far been focused on neural targets \[[@r67], [@r68]\], the existence of ion channel-regulated bioelectric signaling in many cell types \[[@r69]-[@r73]\] and the plethora of ion channel drugs suggest that the next advances in this field will include expanding the use of electroceuticals to harness them in modulating cancer processes. Work dissecting the mechanisms by which bioelectric signals regulate melanocyte conversion implicated serotonergic signaling (Fig. **[9](#F9){ref-type="fig"}**) \[[@r17], [@r60]-[@r62]\]. Depolarized cells produce a serotonin signal that causes melanocytes to undergo a change toward highly metastatic behavior. The characterization of this pathway suggested that blocking serotonin movement across cell membranes could be a promising strategy for the suppression of metastases. Luckily, human-compatible drugs already exist that do precisely this: the class of widely-used serotonin reuptake inhibitors (SSRIs) \[[@r74]\].

3. Neurotransmitters and cancer {#sec3}
===============================

In the nervous system, electrical activity of neurons is coupled to important changes in cell behavior *via* the movement of neurotransmitter molecules. Voltage changes alter the import/secretion of neurotransmitters across membranes. Neurotransmitters such as serotonin are potent mitogens and have many other effects on transcription, cytoskeleton, and cell metabolism. In this way, neurotransmitter dynamics cross cell membranes are a crucial link between bioelectric states and cell behaviors they control. Recent work has shown this relationship to be true outside of the CNS as well \[[@r33], [@r75], [@r76]\].

Neurotransmitter signaling in cancer biology has attracted attention to molecules such as glutamate, glycine, acetylcholine, GABA, and dopamine \[[@r77]-[@r81]\]. Some of the most interesting data implicate serotonin \[[@r82]-[@r88]\], although the epidemiological picture is complicated by the fact that SSRIs are most often used on depressed patients who are undergoing stresses that may alter the

The familiar components of electrical signaling in neurons include resting potential, generated by the activity of ion channels in the cell membrane, and the electrical synapse which allows current to flow into neighboring cells (**A**). These electrical synapses occur in the CNS alongside the much more familiar chemical synapses \[[@r136]-[@r138]\], but are especially crucial outside of excitable tissues for cell regulation and tumor suppression \[[@r139]-[@r142]\]. These same components are present in most somatic cells (**B**), which likewise generate resting potentials and share them with their neighbors using the exact same ion channel and gap junction proteins. Even non-excitable tissues are composed of cell networks (**C**) in which cells coordinate activity and execute group decision-making during pattern generation and maintenance. These networks signal *via* the voltage-dependent movement of small molecules such as serotonin and other neurotransmitters. All of these components have been implicated in various stages of the cancer process. The result of this signaling is growth control, differentiation, pattern regulation -- processes that go awry in cancer. Molecular tools now exist for manipulating bioelectric state of cells (intrinsic plasticity), connectivity of the bioelectric network (synaptic plasticity), or the movement of neurotransmitters within the tissue (network activity). Images courtesy of Jeremy Guay of Peregrine Creative and Alexis Pietak.

Each cell in the organism uses ion channels and pumps to maintain a resting potential (V~mem~) across its plasma membrane (in addition to a number of subcellular gradients, such as nuclear envelope potential, and tissue-level gradients, such as trans-epithelial electric fields). Spatial patterns of resting potential can be detected *in vivo* using voltage-sensitive fluorescent dyes. Here, a fluorescent voltage reporter (Rhodamine 6G dye \[[@r143], [@r144]\], courtesy of Douglas J. Blackiston) applied to a stage 44 frog embryo (Xenopus laevis) illustrates an anterior-posterior physiological gradient across the middle flank of a frog tadpole. The signal has been pseudocolored according to a scale where red is depolarized and purple is hyper-polarized. Such gradients, and their time-dependent changes, reflect the activity of the bioelectric circuits that set up prepatterns driving downstream gene expression and morphogenesis. Schematic of frog embryo was used *via* Xenbase, originally sourced from \[[@r145]\]. Dye map image courtesy of Douglas Blackison. (The color version of the figure is available in the electronic copy of the article).

Cells are regulated by at least two layers of activity: the molecular genetic and the bioelectric (**A**). The molecular-genetic layer of pattern control is implemented by gene regulatory networks in which transcription factors control each other's expression. The bioelectric layer of control is formed by the reciprocal interactions between ion channels and gap junctions, and cell resting potential: V~mem~ is determined by channels and electrical synapses, and at the same time, V~mem~ determines the gating properties of voltage sensitive channels and gap junctions. Thus, every cell has the opportunity to drive positive feedback loops that can amplify small differences (useful for spontaneous symmetry breaking) or negative feedback loops that confer stability and robustness to environmental stimuli. The genetic and bioelectric layers are functionally coupled, since V~mem~ changes can alter transcription of downstream target genes \[[@r146], [@r147]\], while changes in the transcription of ion channel genes alter electric circuit dynamics. Recent data have shown that manipulation of the complex dynamics of the bioelectrical layer reveal its endogenous patterning functions, resulting in the production of frogs with ectopic limbs (**B**), flatworms with 4 heads (**C**), or tadpoles in which gut tissue has been reprogrammed into complete eyes (**D**) \[[@r32], [@r46]\]. Panel A was drawn by Alexis Pietak. The ectopic-limb frog in panel B was obtained from an optogenetic transgenic EnPAC \[[@r148]\] line produced by Gufa Lin. Panels C and D come from references \[[@r46]\] and \[[@r32]\] respectively.

Human oncogenes, when introduced into tadpoles, cause the formation of tumor-like structures (**A**, closeup in A') which exhibit all of the key characteristics of cancer (over-proliferation, tissue disorganization, invasiveness, cancer marker gene expression, etc.). Because aberrant bioelectric signaling is an early component of the carcinogenic process, this transformation is observed *via* voltage-sensitive fluorescent dye signaling (**B**, closeup in B) *in vivo*, revealing the tumor sites and margins before they become anatomically apparent. Consistent with a reversion of cancer into a unicellular phenotype, a wide range of data \[[@r149], [@r150]\] reveal that tumor cells, like stem and early embryonic cells, tend to be depolarized while mature, quiescent somatic cells tend to be hyperpolarized (**C**). Importantly, it is now known that this relationship is not merely a marker, but is actually functionally determinative of cell behavior \[[@r51], [@r52], [@r63], [@r151]\]. Panels A-B' are taken from \[[@r63]\]. The schematic of panel C was drawn by Jeremy Guay of Peregrine Creative, while the voltage diagram of panel C is modified after \[[@r149]\].

background of carcinogenic induction and progression. Our strategy, based on the finding that blockade of serotonin transport efficiently rescued voltage-induced melanoma conversion \[[@r61], [@r62]\], was to explore an SSRI drug that did not cross the blood-brain barrier (an unusual requirement, since all known SSRIs were designed specifically for access to the brain). Such a compound could be expected to exert its protective effects throughout the body without causing the unwanted cognitive effects of SSRIs \[[@r89], [@r90]\]. Thus, we tested Prozac and an analog *in vitro*, to begin to characterize the function of molecules suggested by the above strategy. An additional component that must be considered is the cytoskeleton, as it is known to regulate the distribution of ion channels in a variety of cell types \[[@r91], [@r92]\]. It is also known that ion channels regulate NMDA receptors through microtubules \[[@r93]\]. Moreover, voltage-dependent anion channels are controlled by the c-termini of tubulin \[[@r94]\]. This taken together with previous observations indicates that the microtubule cytoskeleton and ion channels are involved in significant interactions such that regulation of one of these subsystems affects the other. Hence, ion channel regulators may cause downstream effects on microtubules and consequently the use of SSRIs could lead to hitherto unknown effects on cancer cells with potential therapeutic applications.

The cytoskeleton is a target for numerous chemotherapy drugs, many of which bind preferentially to tubulin (so-called tubulin-binding agents or TBAs), such as paclitaxel, vinca alkaloids, laulimalide, peloruside and others \[[@r95]\]. Some of these compounds stabilize microtubules (*e.g*. taxanes) while others destabilize them (*e.g*. vinca alkaloids). Interestingly, it has been also discovered that other classes of compounds, *e.g*. opioids such as noscapine \[[@r96]\] interact with microtubules as well as anesthetics \[[@r97]\]. It is, therefore, not unexpected that compounds which alter mood (psychoactives), for example the antidepressants such as Prozac and its analogs should also interact with microtubules and the cytoskeleton. It is known that they take several weeks for these compounds to achieve their clinical effects in human subjects, apparently because of the need

The black cells in these histological sections of a frog tadpole are melanocytes, pigment cells that normally have a round morphology. Here are shown sections of frog larvae in which a specific cell subpopulation has been artificially depolarized, but no other carcinogenic or mutagenic treatment was applied. In the context of a wild-type genome, the normally small number of round melanocytes seen in sections through the anterior torso (**A**) and the tail (**B**) become highly arborized and over-proliferative (**C**, **D**). These cells become highly migratory, invading the brain and neural tube (**E**, red arrows) and extend long processes as they reach throughout lateral tissues (**F**, red arrow). They also invade blood vessels, which are normally free of melanocytes (**G**) but become choked with these cells after depolarization by pharmacological agents \[[@r61]\] or injection of dominant negative potassium channel subunits (**H**). These animals' normal vasculature (**I**) also begins to overgrow (**J**). Together, these data reveal that depolarization can trigger the key aspects of metastatic melanoma: rapid over-growth, cell shape change, and invasiveness. Panels A-F are taken from \[[@r61]\], panels G,H are taken from \[[@r152]\], and panels I,J are taken from \[[@r60]\]. (The color version of the figure is available in the electronic copy of the article).

for cytoskeletal reconfiguration. Anesthetics also appear to act in microtubules to prevent consciousness, not exclusively on membrane proteins as has been previously assumed \[[@r97]\]. However the effects of anesthesia cannot be readily explained *via* a simple mechanistic mode of action yet. Conversely, it is highly probable that psychoactive compounds should exert cytotoxic effects on cancer cells since microtubules are not only fundamentally important to neuronal cells but are the essential part of the mitotic apparatus (spindles) in dividing cells. Recently, a study was published that reports computational docking of three specific psychotropic compounds Lysergic Acid Diethylamide (LSD-25), heroin (morphine diacetate) and cocaine (benzoylmethylecgonine) to tubulin \[[@r89]\]. It demonstrated significant binding affinity of these compounds to tubulin with unique binding modes and locations compared to the standard control, chemotherapy drug paclitaxel, which has no known involvement in the cognitive process. It was also predicted that the binding affinity of these psychotropic drugs strongly depends on the conformational state of the tubulin dimer. Most importantly, this points to the possibility of off-target interactions of psychoactive drugs, not only binding to their standard receptor sites in neurons but also affecting the cytoskeleton and hence affecting other cellular functions including cell division of dividing cells including cancer cells.

Remarkably, the conversion of normal melanocytes to melanoma is not cell-autonomous (**A**): the depolarized ventral cells in this section through the tadpole trunk are marked with blue *via* b-galactosidase staining, which is at a distance from the cells that respond and convert (the dorsal melanocytes, red arrow). Mechanistic dissection of this process \[[@r60]\] revealed that the long-range communication is mediated by the voltage-dependent release of serotonin from instructor cells (a widely-distributed population that, when depolarized, releases serotonin that activates genes such as *SLUG* and other aspects of epithelial-to-mesenchymal transition in normal melanocytes). The whole process is shown in panel **C**, which reveals how a bioelectric signal is transduced and results in altered system-wide cell behavior. Panels **A**-**B** are taken from \[[@r152]\]. (The color version of the figure is available in the electronic copy of the article).

4. Effects of Psychoactive Compounds on Cancer and Normal Breast Cells {#sec4}
======================================================================

A biophysical perspective suggests serotonergic signaling to be an important control point in the cancer problem, both because of its role as a transducer of bioelectric state and because of its interaction with the cytoskeleton. To examine some of these predictions in a proof-of-concept investigation, we have exposed normal and cancer breast cells to Prozac (Fluoxetine) and its close analog. Fluoxetine, also known by trade names Prozac is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Its chemical formula is C~17~H~18~F~3~NO and its molecular weight is 309.33. It is used for the treatment of major depressive disorder, OCD, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. The analog chosen was: ZINC ID = ZINC06811610 (<http://zinc.docking.org/>) with a chemical formula C15H23NO4 and a popular name = 2-\[[@r3]-hydroxy-3-(4-propoxyphenyl)-propyl\] aminopropanoic. It has a polar surface area = 86 in the units of Angstrom squared. Its molecular weight is 281.352. This is one of several compounds similar to Prozac that can be found in the ZINC database, which may have high DMSO solubility because of smaller radii of gyration and lower lipophilicity and hence are also less likely to cross the blood brain barrier.

Optogenetics \[[@r153]-[@r155]\] is the use of light-gated ion channels to gain spatio-temporal control of bioelectrical state of cells *in vivo* (**A**). Recent data have shown that when light-gated channels such as channelrhodopsin are co-injected with oncogenes (**B**), the incidence of resulting tumors can be reduced by light exposure which forces hyperpolarization and thus antagonizes the steps by which oncoproteins transform cells. This occurs by prevention of tumor formation and tumor normalization. Such therapies, especially when combined with novel chemical strategies to render ion cannels light-gated without the use of gene therapy \[[@r156], [@r157]\], are a promising novel path forward for cancer treatments that focus on tumor reprogramming instead of targeted toxicity. Panel A was drawn by Jeremy Guay of Peregrine Creative, while panels B, C are taken from \[[@r66]\].

The binding affinities of Fluoxetine for its receptor targets is in the range of 1 nM (for SERT) to 72.6 nM (5-HT~2C~, 200nM for 5-HT~2A~ and 4 uM for 5-HT~2B~ \[[@r98], [@r99]\]. A number of other receptors are characterized by Fluoxetine's affinity in the low micromolar range (*e.g*. M~1~, M~2~, M~3~, M~4~, M~5~ and H~1~). To the best of our knowledge, it's affinity for tubulin has not been reported so far. Based on previous studies of binding of psychoactive compounds to tubulin mentioned above we expect Fluoxetine to have an off-target interaction with tubulin and microtubules and hence cytotoxic properties we examined and report here for the first time.

The survival of two cell lines: breast cancer cell line and a corresponding normal breast cell line (MCF7 and MCF10A) after exposure to the ligands was evaluated by an MTT and a proliferation assay. Here, MCF-10A was used as a reference since its immortal transformation allows its *in vitro* culture and it is not malignant. We performed an MTT assay to determine the survival of these cell lines and a Crystal violet staining assay for proliferation analysis for both compounds. In [Figs. (**10)**](#F10){ref-type="fig"} and (**11)** we show the data for the MTT and proliferation assays for Prozac while in [Figs. (**12)**](#F12){ref-type="fig"} and (**13)** similar data are shown for the Prozac analog. We found an IC50 value for the concentration of these compounds (25 μM for Prozac and 100 μM for the Prozac analog) at which these compounds inhibited tumor cell survival and proliferation. Additionally, at these concentrations we did not observe alterations in a non-tumoral cell (see the panels in [Figs. (**10**](#F10){ref-type="fig"}-[**13**](#F13){ref-type="fig"}**)** corresponding to MCF-10A). While these IC50 concentrations are higher than the concentration values for the kinetically determined affinities for the primary receptor targets of Prozac mentioned above, they are not negligible especially in view of pharmacokinetic considerations that may be brought to bear on the delivery of these compounds to the tumor site. Importantly, the bioavailability of fluoxetine is very high (72%), and peak plasma concentrations are reached in 6--8 hours. It is highly bound to plasma proteins, mostly albumin and α~1~-glycoprotein \[z\]. The extremely slow elimination of fluoxetine and its active metabolite norfluoxetine from the body distinguishes it from other antidepressants. Fluoxetine elimination half-life changes from 1 to 3 days, after a single dose, to 4 to 6 days, after long-term use \[[@r100]\]. Its therapeutic dose for depression depends ranges between 10 and 80 mg a day and a maximum dose is 90 mg. The latter translates into an approximate concentration in the blood at 300 mM, which is much higher than the IC50 value determined in this study.

5. Materials and Methods {#sec5}
========================

5.1. Reagents, Cell Lines and Culture Conditions {#sec5.1}
------------------------------------------------

Unless stated otherwise, all chemical and tissue culture reagents were purchased from Sigma-Aldrich (Oakville, Canada) and tissue culture reagents from Invitrogen (Burlington, Canada), respectively. MCF-7 (Luminal A) and the non-tumoral breast epithelial cell line MCF-10A were maintained in MEM media supplemented with 10% FBS and 1% PSK.

5.2. Cell Proliferation and Survival Assays {#sec5.2}
-------------------------------------------

For cell growth, replicate cultures were established 48 h after transfection in 24-well plates (Sarstedt, Canada) at 5 x 10^4^ cells/well. At 24, 48, 72 and 96 h after plating, cultures were trypsinized, stained with trypan blue and counted using hemocytometer. The total number of cells/well for each cell line was calculated and plotted for each time point. For further verification, we also assessed cell proliferation by crystal violet staining. Cells were plated in 96-well microtiter plates at 5 x 10^3^ cells/well. At specific time points, cells were washed with PBS, fixed with glutaraldehyde for 10 min, and stained with 0.1% (W/V) crystal violet in 0.2% (V/V) Triton X-100. Microtiter plates were read on a spectrophotometer at 570 nm.

For cell survival, cells were plated in 96-well plate at 5 x 10^3^ cells/well. At 24, 48, 72 and 96 h, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) was added to each well, and the plates were incubated at 37°C for another 4 h at which time the resulting formazan crystals were solubilized by the addition of 200 μl of MTT solubilization solution. The absorbance at 570 nm was recorded using a microplate reader (Bio Tek Instruments, Winooski, VT, USA). Each experiment for each cell lines was repeated 3-5 times.

Conclusion
==========

Cancer is the uncontrolled cell growth in which the cells show invasive intrusion or destruction of adjacent tissues and metastasize to other locations in the body *via* lymph and /or blood. Cancer cells escape the normal control of cell division and programmed cell death. The conventional methods to treat metastatic cancer are chemotherapy and radiation therapy. But these have a major drawback of producing severe side effects as they cannot differentiate between the cancerous cells and the normal cells. The "normal" cells most commonly affected by chemotherapy are the blood cells, the cells in the mouth, stomach and bowel, and the hair follicles; resulting in low blood counts, mouth sores, nausea, diarrhea, and/or hair loss. Therefore, recently the focus has shifted to comparatively newer methods of cancer treatment, *i.e*. targeted cancer therapy, which uses drugs or other substances to identify and attack cancer cells thereby avoiding any damage to normal cells. In this paper, we have advanced a new hypothesis that reprogramming of tumor cells can be achieved by avoiding toxic chemotherapy and instead by using a completely different set of pharmacological agents, in particular psychoactive compounds. Their repurposing can be achieved by rational drug design \[[@r101]\] involving derivatization that should take into account the molecular structure of the target and such aspects as blood-brain-barrier permeation.

A view of cancer as a disease of pattern coordination is complementary and distinct from the prevailing paradigm that sees cancer as arising from genetically damaged cells, which are irrevocably broken \[[@r102], [@r103]\]. It has long been known that appropriate patterning environments, such as embryos and regenerating limbs \[[@r15], [@r104]\], can normalize aggressive transformed cells. Likewise, cancer can be induced by factors such as denervation, barriers made from non-carcinogenic substances, and even apposition of healthy but ectopic tissues \[[@r17]\]. It is clear that at least in some cases, the process is fundamentally physiological, not genetic, and thus could potentially be reversed \[[@r105], [@r106]\]. Strategies which seek to manipulate the environment to normalize or reprogram tumors \[[@r107], [@r108]\], and thus avoid toxic chemotherapy and the compensatory growth and tumor evolution that plagues conventional approaches, could be an important frontier in this field.

Future work in this emerging field will focus on the role of neurotransmitters in mediating long-range growth control signals, resulting in a better understanding of the limits of the "microenvironment" and strategies for manipulating endogenous morphogenetic cues for cancer prevention and normalization. The numerous drugs emerging from psychopharmacology form an exciting toolkit with which to address the subcellular and network-level mechanisms that go awry in cancer. In parallel with the modeling and *in vivo* studies of neurotransmitter pathways in computational psychiatry, a combined understanding of cytoskeletal, bioelectric, and neurotransmitter signaling in cellular networks is likely to have profound implications for novel approaches to the cancer problem.
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![Normalization of cancer by actively patterning environments.\
(**A**) Cancer cells introduced into embryonic environments are able to participate in normal development and contribute to healthy organs \[[@r104], [@r130]\]. (**B**) Similarly, tumors induced on limbs of regenerative species become normalized if the process of regeneration is induced \[[@r131]-[@r134]\]. These examples reveal that at least in some cases, cancer is not irrevocable cell-autonomous damage but a reversible network disorder -- an error of communication and geometry \[[@r135]\]. Images courtesy of Jeremy Guay of Peregrine Creative.](CPD-23-4827_F2){#F2}
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![Non-cell-autonomous signaling *via* serotonin underlies voltage-mediated conversion to metastasis.](CPD-23-4827_F8){#F8}
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![MMT survival assay results for Prozac-exposed MCF7 breast cancer cells (top panel) and MCF10A non-malignant breast cells (bottom panel) at 24h, 48h and 72 h, respectively, from left to right.](CPD-23-4827_F10){#F10}

![Crystal violet staining proliferation assay results for Prozac-exposed MCF7 breast cancer cells (top panel) and MCF10A non-malignant breast cells (bottom panel) at 24h, 48h and 72 h, respectively, from left to right.](CPD-23-4827_F11){#F11}

![MMT survival assay results for the Prozac analog-exposed MCF7 breast cancer cells (top panel) and MCF10A non-malignant breast cells (bottom panel) at 24h, 48h and 72 h, respectively, from left to right.](CPD-23-4827_F12){#F12}

![Crystal violet staining proliferation assay results for the Prozac analog-exposed MCF7 breast cancer cells (top panel) and MCF10A non-malignant breast cells (bottom panel) at 24h, 48h and 72 h, respectively, from left to right.](CPD-23-4827_F13){#F13}

###### 

list of ion channel oncogenes.

  **Ion Translocator Protein**         **Species**    **References**         **Cancer-relevant role**
  ------------------------------------ -------------- ---------------------- --------------------------
  NaV1.5 sodium channel                Human          \[[@r109], [@r110]\]   Oncogene
  ERG potassium channels               Human          \[[@r111]-[@r113]\]    Oncogene
  KCNK9 potassium channel              Mouse          \[[@r114]\]            Oncogene
  Ductin (proton V-ATPase component)   Mouse          \[[@r115]\]            Oncogene
  SLC5A8 sodium/butyrate transporter   Human          \[[@r116]\]            Oncogene
  KCNE2 potassium channel              Mouse          \[[@r117]\]            Oncogene
  KCNQ1 potassium channel              Human, mouse   \[[@r118]-[@r120]\]    Oncogene
  SCN5A voltage-gated sodium channel   Human          \[[@r121]\]            Oncogene
  Metabotropic glutamate receptor      Mouse, Human   \[[@r122]-[@r124]\]    Oncogene
  CFTR chloride channel                Human          \[[@r125], [@r126]\]   Tumor suppressor
  Connexin43                           Human          \[[@r127]\]            Tumor suppressor
  BKCa                                 Human          \[[@r128]\]            Oncogene
  Muscarinic Acetylcholine receptor    Human, mouse   \[[@r129]\]            Tumor suppressor
